At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 191 enrolled
Drug / intervention
EXPAREL 266 mg +1 moredrug
Likely dose
EXPAREL 266 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy
In Brief
A Phase 3 clinical trial evaluating EXPAREL 266 mg and Placebo for Posterolateral Thoracotomy and Postoperative Pain. Completed, enrolled 191 participants across 21 sites in 5 countries.
Detailed Summary
The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPosterolateral Thoracotomy, Postoperative Pain
CountriesBulgaria, Czechia, Georgia, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedMar 2013
Primary CompletionJun 2013
TodayJul 2026
First PostedMar 1, 2013
Enrollment StartDec 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.3 years ago
Interventions
EXPAREL 266 mgdrug
Placebodrug